TuHURA Biosciences, Inc. - Common Stock (HURA)

TuHURA Biosciences (NASDAQ:HURA) outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

These stocks have an unusual volume in today's session

The merger brings together two biotech firms aiming to tackle immune resistance in cancer, with plans to advance programs targeting Merkel Cell Carcinoma.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.